In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

How do you answer a 20-year-old when they ask: can I participate in competitive sports? Long questionnaire

The sudden, unexpected death of a young athlete is a tragedy unparalleled in sports, which leads to grief among friends, family members and community. Sudden death in athletes attracts large amounts of media attention. Expanding the current criteria for pre-participation screening in young athletes may improve outcomes in some cases. The recommendations and opinions have varied from obtaining a detailed history and physical examination alone to use of an electrocardiogram (ECG). The addition of an echocardiogram, computed tomography (CT) scan, cardiac magnetic resonance imaging (CMR), stress test and Holter monitor for rhythm monitoring when indicated can substantially improve the diagnostic ability of the treating clinician.

Sports Cardiology


Any young individual who intends to participate in competitive sports needs to be screened in detail for risk factors and fitness to prevent the sad and disheartening situation of sudden cardiac death (SCD). SCD is defined as death due to a cardiovascular cause within one hour of onset of symptoms. The prevalence of cardiovascular disease leading to SCD in young athletes is around 0.2%-0.7% [1]. Maron et al reported 0.6 SCD per 100,000 person-years in young competitive athletes in the USA [2]. Corrado et al studied SCD incidence in young Italian players and reported 3.6/100,000 person- years before routine pre-participation screening (PPS) and an incidence of 0.4/100,000 person-years after starting routine PPS [3]. An Italian study comparing the fatality among non-athletic young individuals and young competitive athletes showed 0.9/100,000/year and 2.3/100,000 athletes per year, respectively, suggesting that physical activity in this age group increases the risk of sudden death by 2.5-fold [4].

The various aetiologies of SCD in young athletes are listed in Table 1.


Table 1.

Common cardiovascular diseases causing sudden cardiac death in athletes
Hypertrophic cardiomyopathy (HCM) Trauma (commotio cordis)
Congenital heart disease Rupture of ascending aorta
Arrhythmogenic right ventricular cardiomyopathy (ARVC) Mitral valve prolapse (MVP), congenital aortic stenosis
Myocarditis Anomalous origin of coronary arteries (AOCA)
Wolff-Parkinson-White (WPW) syndrome Hypothermia or hyperthermia
Long QT syndrome Drugs (cocaine, amphetamine)
Early repolarisation syndrome Electrolyte imbalance
Premature coronary artery disease Unexplained


History and physical examination

It is important to obtain a detailed history and conduct a physical examination of young athletes planning to take part in competitive sports. A retrospective study found that 29% of athletes who had SCD had symptoms suggesting cardiac disease before cardiac arrest [5]. A history of present illness, past history and family history will give an insight into the probability of SCD during pre-participation screening. The relevant questions need to be asked after taking the anthropometric data such as height and weight of the young athlete. The physical examination should include comparison of blood pressure in both arms, auscultation for presence of murmurs and examination for features of Marfan syndrome. The routinely asked questions include [6]:

  • History of dizziness, chest pain or shortness of breath during or post exercise?
  • Any first-degree relatives who have died suddenly or had premature significant cardiac disease under the age of 60 years?


12-lead ECG

Routine use of ECG for screening athletes has a low specificity and therefore needs strict interpretation criteria. An ECG has been shown to detect hypertrophic cardiomyopathy (Figure 1) in 50%-75% of asymptomatic young athletes and 25% of adolescents with arrhythmogenic right ventricular cardiomyopathies [7]. Premature coronary artery disease may go undetected by ECG alone and warrants further evaluation. Primary electrical diseases are inherited genetic alterations in cell ionic and electric behaviour which lead to arrhythmias and SCD and include Wolff-Parkinson-White syndrome, long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT) and idiopathic ventricular fibrillation.


Figure 1. Electrocardiogram in apical hypertrophic cardiomyopathy showing repolarisation changes and giant inverted T-wave in the anterolateral leads.

243_Sachdeva_Figure 1.jpg





The cost-effectiveness of an ECG has been reported from studies in the USA which showed that the cost per athlete life saved ranges from US $44,000 to $204,000 [8]. ECG interpretation with international recommended criteria was associated with significant reductions in secondary investigations and has been shown to reduce the cost of ECG screening by nearly 25% without compromising the ability to identify serious cardiac disease [9]. In 2017, international recommendations were devised by a group of American and European experts with the aim of unifying the recommendations for interpretation of the athlete’s ECG [10, 11]. These recommendations take into account adolescent athletes, black ethnicity and some non-specific electrical anomalies, notably axis deviation and voltage criteria for atrial enlargement, as shown in Table 2.


Table 2. International consensus standards for electrocardiographic interpretation in athletes (with permission from Dhutia et al [11]).

Normal    Borderline* Abnormal   
QRS voltage consistent for LVH or RVH        Left axis deviation T-wave inversion
Incomplete RBBB Left atrial enlargement ST-segment depression
Early repolarisation/ST-segment elevation     Right axis deviation Pathologic Q-waves
ST-segment elevation and TWI V1–V4 in black athletes Right atrial enlargement Complete LBBB
TWI V1–V3 age <16 years old Complete RBBB QRS ≥140 ms duration
Sinus bradycardia or arrhythmia   Epsilon wave
Ectopic atrial or junctional rhythm   Prolonged QT interval
1st degree AV block   Ventricular pre-excitation
Mobitz type I 2nd degree AV block   Brugada type 1 pattern
    Profound sinus bradycardia <30 bpm
    PR interval ≥400 ms
    Mobitz type II 2nd degree AV block
    3rd degree AV block
    ≥2 PVCs
    Atrial tachyarrhythmias
    Ventricular tachyarrhythmias

* Further evaluation if two or more ‘borderline’ ECG findings identified. Further evaluation required in the presence of any ‘abnormal’ ECG finding.

No further evaluation required if ‘normal’ ECG findings are found in asymptomatic athletes who report no family history of inherited cardiac disease or SCD.

AV: atrioventricular block; ECG: electrocardiogram; LBBB: left bundle branch block; LVH: left ventricular hypertrophy; PVC: premature ventricular contraction; RBBB: right bundle branch block; RVH: right ventricular hypertrophy; SCD: sudden cardiac death; TWI: T-wave inversion


The above-mentioned methods of cardiovascular screening by history, physical examination and ECG have limitations, although the addition of ECG interpretation standards enhances the ability to diagnose underlying pathologies. However, many disease processes may remain undiagnosed and warrant further evaluation. While echocardiography may identify additional structural disorders, there is insufficient evidence to recommend an echocardiogram for routine screening [12]. The diagnosis on an echocardiogram may at times need to be confirmed and substantiated by use of more diagnostic tools such as a computed tomography (CT) scan or cardiac magnetic resonance imaging (CMR) for confirmation of anatomy, and stress testing and Holter monitoring to study exercise tolerance and to unearth underlying arrhythmias in young athletes.

Echocardiogram and other imaging modalities

Echocardiography is a very useful and non-invasive technique which can help the clinician to find the structural heart disease leading to SCD with high sensitivity and specificity. The various presentations of an echocardiogram and further diagnostic tests when indicated in some specific structural abnormalities are discussed as follows.

Hypertrophic cardiomyopathy

Measurements of left ventricular (LV) wall thickness in end diastole are carried out, preferably in short axis at the mitral, mid LV and apical levels. An LV wall thickness of ≥15 mm in one or more myocardial segments in adults is essential for diagnosis [13]. Screening of first-degree relatives in such cases is also important. Systolic anterior motion (SAM) of mitral leaflets producing LV outflow tract obstruction (LVOTO) in hypertrophic cardiomyopathy (HCM) is defined as an instantaneous peak Doppler LVOTO pressure gradient ≥30 mmHg at rest or during physiological provocation (Valsalva manoeuvre). Strain and strain rate are reduced in spite of a normal ejection fraction (EF), more at the site of hypertrophy. This also helps us to pick up a subclinical disease well before increased wall thickness is evident, as shown in Figure 2.


Figure 2. Speckle tracking strain bull’s eye in hypertrophic cardiomyopathy showing diffuse Impairment.

243_Sachdeva_Figure 2.jpg




Idiopathic dilated cardiomyopathy

Mild LV cavity enlargement may be encountered in athletes; however, the indexed LV cavity dimension does not fall within pathological limits. The biplane modified Simpson’s rule to measure EF is operator dependent; therefore, three‑dimensional echocardiography helps to improve the LV volume calculation and EF reproducibility. Abnormal sphericity index is noted in idiopathic dilated cardiomyopathy (IDC), which is calculated by the ratio of length (mitral annulus to apex in the apical view) and diameter (mid‑cavity level in the short‑axis view). The adaptive cardiac remodelling shows normal or even supranormal values of strain and strain rate, while in IDC patients these values are reduced. Stress echocardiography is of assistance in differentiating physiological LV remodelling which shows normal or supranormal contractile reserve, while a reduced EF recovery is suggestive of IDC [14].

Non-compaction cardiomyopathy

Left ventricular non-compaction cardiomyopathy (LVNC) is a rare form of cardiomyopathy caused by arrest of normal myocardial development characterised by multiple deep ventricular trabeculations and is associated with exercise-related SCD in athletes who may be otherwise asymptomatic and undiagnosed. Studies have reported trabeculations in 20% of athletes, and about 8% had conventional criteria for the diagnosis of LVNC; this prevalence increased to 13% when only black athletes were considered. This high prevalence could be due to expression of cardiac adaptation to increased preload and afterload, influenced by genetic factors. Echocardiographic characteristics are useful to distinguish between normal and pathological pattern: the site of trabeculations (apical region in LVNC cardiomyopathy vs mid‑cavity region in athletes), systolic and diastolic function (reduced in LVNC vs normal in athletes), and the preservation of contractile reserve at stress echocardiography in athletes with hypertrabeculation [15].

Anomalous origin of coronary arteries

Anomalous origin of coronary arteries (AOCA) is a frequent cause of SCD during sports and is a rare congenital disease. This subset of individuals is mostly asymptomatic: they have a normal ECG or may rarely present with syncope or chest pain on exertion. Echocardiography is utilised to visualise the origin of both proximal left and right coronary arteries from the coronary sinuses. The main AOCAs associated with SCD in athletes include the origin of the left main coronary artery from the right aortic sinus and the origin of the right coronary artery from the left sinus [16]. Transthoracic echocardiography (TTE) in the parasternal short‑axis view in the plane of the aortic root may distinguish the two coronary ostia and even identify the initial course of the coronary arteries. Colour Doppler echo is useful to identify the proximal course of the coronary arteries. Definitive diagnosis relies on imaging tests such as CMR or CT coronary angiography, which allow an accurate demonstration of the anomalous coronary artery origin and course.

Valvular heart disease

Several studies have reported SCD in young asymptomatic individuals with mitral valve prolapse (MVP) [17]. Echocardiography shows systolic bulging of one or both leaflets towards the left atrium (>2 mm) beyond a line connecting the annular hinge point. Leaflets are generally elongated and thickened with thickness ≥5 mm. A mitral annulus enlarged over 28 mm is associated with mitral annular disjunction (MAD). Mitral regurgitation (MR) evaluation is carried out using colour flow Doppler to evaluate the haemodynamic consequences of MR. MR occurs typically in mid‑to‑late systole and is associated with progressive left cardiac chamber dilatation. The complications of MVP are ventricular and supraventricular arrhythmias, whereas MR has been demonstrated to be an independent risk factor for producing arrhythmias. Young women with a bileaflet MVP or inverted T-waves in the inferior leads and right bundle branch block have been shown to have complex ventricular arrhythmias.

Premature coronary artery disease

Premature coronary artery disease (CAD) is an important substrate for SCD in young people and athletes. SCD is often the first manifestation of the disease in such cases without a past history of angina or myocardial infarction. The proximal left anterior descending coronary artery is the typical culprit vessel. Echocardiography and exercise testing may fail to show myocardial ischaemia or arrhythmias. Rarely, an echo‑inducible myocardial ischaemia may be demonstrated by stress echocardiography.


Myocarditis accounts for 5%-22% of SCDs in younger populations, more so during exercise. Myocarditis provides a myocardial electrical substrate for life‑threatening ventricular arrhythmias and SCD. An echocardiogram shows global LV dysfunction and may sometimes show regional wall motion abnormalities (RWMA) or pericardial effusion. Myocardial fibrosis is confined to a small myocardial area and involves outer wall layers without decreasing the myocardial thickening; thus, the scar is usually undetectable by echocardiography [18]. A delayed gadolinium enhancement on CMR is useful for scar identification. Avoidance of competitive activity for such athletes is essential, and regular follow-up with the cardiologist is required.

Dissection of the aorta

Dissection of the aorta is a catastrophic complication which may occur in the presence of Marfan syndrome. Measurement of the aorta using an echocardiogram and a CT scan are recommended when needed [19]. Mild aortic enlargement may be noted in athletes due to intense physical training which should not be confused with underlying aortopathy. Therefore, follow-up for aorta dimensions may be needed whenever aortopathy is suspected.

Arrhythmogenic right ventricular cardiomyopathy

Arrhythmogenic right ventricular cardiomyopathy (ARVC) increases the risk of SCD in athletes by 5-fold because of progressive loss of myocytes and replacement by fibro-fatty tissue, creating the substrate for ventricular arrhythmias. ARVC is present in 4%-22% of athletes with SCD. A meta‑analysis showed that subjects with ARVC had a larger RV outflow tract (RVOT), lower tricuspid annular plane systolic excursion (TAPSE) and myocardial strain compared with healthy controls [20]. ARVC patients show a disproportionate enlargement of the RVOT along with significant RV motion abnormalities.


An ECG cannot detect all disorders leading to SCD in athletes, and prevention of SCD in young athletes remains the priority of the sports medicine community. There is a compelling argument that resources would be better utilised in improving facilities, training and availability of cardiopulmonary resuscitation and automated external defibrillators (AED). Early identification of individuals at risk through screening is an important strategy to reduce the overall burden of SCD in young athletes. Despite the variety of causes of SCD, only a few conditions are responsible for most deaths. Most athletes who eventually succumb to SCD have no history of cardiac problems (family or personal) and no symptoms before death. Hence, the detection of at-risk individuals poses a significant challenge in sports medicine. As physicians, we recognise that athletic participation carries inherent risks. An enormous amount of research has been done during the past years evaluating the causes and events surrounding SCD and potential screening mechanisms for identifying those at risk. 


A long list of tests should be recommended whenever there is any suspicion of developing SCD from family or personal history, clinical examination and ECG. Further evaluation by more tests is necessary in case two or more borderline ECG findings are identified, as per the above-mentioned international ECG criteria and in the presence of any abnormal ECG finding. Asymptomatic athletes with a normal ECG who report no family history of inherited cardiac disease or SCD are not risk-free, as discussed, and one may find a hidden cause if they are given a thorough work-up. The long list of investigations is obviously more expensive but, in some cases, it can be seen to help to decrease SCD effectively. The athletic trainer, in collaboration with the team physician, can implement changes to develop more prudent and effective means of screening for potential cardiac anomalies for prevention of sudden cardiac death.


  1. Corrado D, Pelliccia A, Bjørnstad HH, Vanhees L, Biffi A, Borjesson M, Panhuyzen-Goedkoop N, Deligiannis A, Solberg E, Dugmore D, Mellwig KP, Assanelli D, Delise P, van-Buuren F, Anastasakis A, Heidbuchel H, Hoffmann E, Fagard R, Priori SG, Basso C, Arbustini E, Blomstrom-Lundqvist C, McKenna WJ, Thiene G; Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Cardiovascular pre-participation screening of young competitive athletes for prevention of sudden death: proposal for a common European protocol. Consensus Statement of the Study Group of Sport Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology. Eur Heart J. 2005;26:516‑24. 
  2. Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller FO. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980‑2006. Circulation. 2009;119:1085‑92. 
  3. Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? J Am Coll Cardiol. 2003;42:1959‑63. 
  4. Corrado D, Zorzi A. Sudden death in athletes. Int J Cardiol. 2017;237:67‑70. 
  5. Finocchiaro G, Papadakis M, Robertus JL, Dhutia H, Steriotis AK, Tome M, Mellor G, Merghani A, Malhotra A, Behr E, Sharma S, Sheppard MN. Etiology of sudden death in sports insights from a United Kingdom regional registry. J Am Coll Cardiol. 2016;67:2108-15. 
  6. Maron BJ, Thompson PD, Ackerman MJ, Balady G, Berger S, Cohen D, Dimeff R, Douglas PS, Glover DW, Hutter AM Jr, Krauss MD, Maron MS, Mitten MJ, Roberts WO, Puffer JC; American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007;115:1643-55. 
  7. McGuinty C, Dorian P, Connelly K, Chan R, Adler A, Rakowski H, Aves T, Laandry C. How accurate is the ECG in screening for hypertrophic cardiomyopathy? Can J Cardiol. 2018;34(Suppl 1):S152. 
  8. Fuller CM. Cost effectiveness analysis of screening of high school athletes for risk of sudden cardiac death. Med Sci Sports Exerc. 2000;32:887-90. 
  9. Dhutia H, Malhotra A, Finocchiaro G, Merghani A, Papadakis M, Naci H, Tome M, Sharma S. Impact of the international recommendations for electrocardiographic interpretation on cardiovascular screening in young athletes. J Am Coll Cardiol. 2017;70; 805-7. 
  10. Sharma S, Drezner JA, Baggish A, Papadakis M, Wilson MG, Prutkin JM, La Gerche A, Ackerman MJ, Borjesson M, Salerno JC, Asif IM, Owens DS, Chung EH, Emery MS, Froelicher VF, Heidbuchel H, Adamuz C, Asplund CA, Cohen G, Harmon KG, Marek JC, Molossi S, Niebauer J, Pelto HF, Perez MV, Riding NR, Saarel T, Schmied CM, Shipon DM, Stein R, Vetter VL, Pelliccia A, Corrado D. International recommendations for electrocardiographic interpretation in athletes. J Am Coll Cardiol. 2017;69:1057-75. 
  11. Dhutia H, MacLachlan H. Cardiac screening of young athletes: a practical approach to sudden cardiac death prevention. Curr Treat Options Cardio Med. 2018;20:85. 
  12. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, Collet JP, Corrado D, Drezner JA, Halle M, Hansen D, Heidbuchel H, Myers J, Niebauer J, Papadakis M, Piepoli MF, Prescott E, Roos-Hesselink JW, Graham Stuart A, Taylor RS, Thompson PD, Tiberi M, Vanhees L, Wilhelm M; ESC Scientific Document Group. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42:17-96. 
  13. Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, Mahrholdt H, McKenna WJ, Mogensen J, Nihoyannopoulos P, Nistri S, Pieper PG, Pieske B, Rapezzi C, Rutten FH, Tillmanns C, Watkins H. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733‑79. 
  14. Lakdawala NK, Thune JJ, Colan SD, Cirino AL, Farrohi F, Rivero J, McDonough B, Sparks E, Orav EJ, Seidman JG, Seidman CE, Ho CY. Subtle abnormalities in contractile function are an early manifestation of sarcomere mutations in dilated cardiomyopathy. Circ Cardiovasc Genet. 2012;5:503‑10. 
  15. Gati S, Chandra N, Bennett RL, Reed M, Kervio G, Panoulas VF, Ghani S, Sheikh N, Zaidi A, Wilson M, Papadakis M, Carré F, Sharma S. Increased left ventricular trabeculation in highly trained athletes: do we need more stringent criteria for the diagnosis of left ventricular non‑compaction in athletes? Heart. 2013;99:401-8. 
  16. Basso C, Maron BJ, Corrado D, Thiene G. Clinical profile of congenital coronary artery anomalies with origin from the wrong aortic sinus leading to sudden death in young competitive athletes. J Am Coll Cardiol. 2000;35:1493‑501. 
  17. Spartalis M, Tzatzaki E, Spartalis E, Athanasiou A, Moris D, Damaskos C, Garmpis N, Voudris V. Mitral valve prolapse: an underestimated cause of sudden cardiac death‑a current review of the literature. J Thorac Dis. 2017;9:5390‑8. 
  18. Zorzi A, Perazzolo Marra M, Rigato I, De Lazzari M, Susana A, Niero A, Pilichou K, Migliore F, Rizzo S, Giorgi B, De Conti G, Sarto P, Serratosa L, Patrizi G, De Maria E, Pelliccia A, Basso C, Schiavon M, Bauce B, Iliceto S, Thiene G, Corrado D. Nonischemic left ventricular scar as a substrate of life‑threatening ventricular arrhythmias and sudden cardiac death in competitive athletes. Circ Arrhythm Electrophysiol. 2016;9:e004229. 
  19. Devereux RB, de Simone G, Arnett DK, Best LG, Boerwinkle E, Howard BV, Kitzman D, Lee ET, Mosley TH Jr, Weder A, Roman MJ. Normal limits in relation to age, body size and gender of two‑dimensional echocardiographic aortic root dimensions in persons ≥15 years of age. Am J Cardiol. 2012;110:1189-94. 
  20. Qasem M, Utomi V, George K, Somauroo J, Zaidi A, Forsythe L, Bhattacharrya S, Lloyd G, Rana B, Ring L, Robinson S, Senior R, Sheikh N, Sitali M, Sandoval J, Steeds R, Stout M, Willis J, Oxborough D. A meta-analysis for echocardiographic assessment of right ventricular structure and function in ARVC. Echo Res Pract. 2016;3;95-104. 

Notes to editor


Ankush Sachdeva, MD
Consultant Non-Invasive Cardiology, Fortis Escorts Heart Institute, Okhla, New Delhi, India


Address for correspondence:

Dr Ankush Sachdeva, 78, second floor, Rajdhani enclave, Pitampura, Delhi-110034, India
E-mail: / 


Author disclosures:

The author has no conflicts of interest to declare.


The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.